A disseminated Mycobacterium marinum infection in a renal transplant HIV-infected patient successfully treated with a bedaquiline-containing antimycobacterial treatment: A case report

Meybeck, Agnès; Tétart, Macha; Baclet, V.; Alcaraz, I.; Blondiaux, Nicolas; Peytavin, Gilles; Veyziris, Nicolas; Robineau, Olivier; Senneville, Éric

doi:10.1016/j.ijid.2021.04.054

Cited by 10 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment duration varied between 3.5 and 18 months. Although some adverse events such as nausea 66 and a mild QTc prolongation in one case 63 were reported, bedaquiline was well tolerated.…”

Section: Resultsmentioning

confidence: 90%

“…Of the eight human studies identified, four were case series 11 , 62 , 65 , 67 and four were case reports (Table 3 ). 63 , 64 , 66 , 68 Two of the studies were conducted by the same group 11 , 62 and had an overlap of four patients infected with M. intracellulare . However, the analyses done by these studies were completely different.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis

Omar,

Whitfield,

Nolan

et al. 2023

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Background Non-tuberculous mycobacteria (NTM) infections are increasing in incidence and associated mortality. NTM are naturally resistant to a variety of antibiotics, complicating treatment. We conducted a literature assessment on the efficacy of bedaquiline in treating NTM species in vitro and in vivo (animal models and humans); meta-analyses were performed where possible. Method Four databases were searched using specific terms. Publications were included according to predefined criteria. Bedaquiline’s impact on NTM in vitro, MICs and epidemiological cut-off (ECOFF) values were evaluated. A meta-analysis of bedaquiline efficacy against NTM infections in animal models was performed. Culture conversion, cure and/or relapse-free cure were used to evaluate the efficacy of bedaquiline in treating NTM infection in humans. Results Fifty studies met the inclusion criteria: 33 assessed bedaquiline’s impact on NTM in vitro, 9 in animal models and 8 in humans. Three studies assessed bedaquiline’s efficacy both in vitro and in vivo. Due to data paucity, an ECOFF value of 0.5 mg/mL was estimated for Mycobacterium abscessus only. Meta-analysis of animal studies showed a 1.86× reduction in bacterial load in bedaquiline-treated versus no treatment within 30 days. In humans, bedaquiline-including regimens were effective in treating NTM extrapulmonary infection but not pulmonary infection. Conclusions Bedaquiline demonstrated strong antibacterial activity against various NTM species and is a promising drug to treat NTM infections. However, data on the genomic mutations associated with bedaquiline resistance were scarce, preventing statistical analyses for most mutations and NTM species. Further studies are urgently needed to better inform treatment strategies.

show abstract

Section: Resultsmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 99%

Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis

Omar,

Whitfield,

Nolan

et al. 2023

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

“…For both MT and NTM treatment and management are the same as in the general population [43], but therapy of these infections is complicated by pharmacological interactions with immunosuppressive regimens and the additive renal and hepatic toxicities in the long term [38,44]. There is little experience on newer agents such as clofazimine and bedaquiline, but have been safely used in a small retrospective SOT series [45,46].…”

Section: Tuberculous and Non-tuberculous Mycobacteriamentioning

confidence: 99%

Skin and soft tissue infections in solid organ transplants

Peghin,

Graziano,

Grossi

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Skin and soft tissue infections (SSTI) in solid organ transplant (SOT) recipients may be a great challenge for clinicians caring for SOT due to the involvement of both common and opportunistic pathogens associated with a blunted immune response. The purpose of this review is to outline current literature and describe open issues on the management of SSTI in this special population. Recent findings Clinical presentation in SOT recipients can manifest as isolated skin lesions after primary inoculation or be the sign of a disseminated infection. Tissue samples for microscopy and histopathology are crucial to making an accurate diagnosis given the nonspecific and heterogeneous appearance of skin lesions. Multidisciplinary teams are required for a comprehensive diagnosis and management. Summary SSTI are frequent contributors to morbidity and mortality in SOT. Specific research focused on the clinical presentation, risk factors and management in this special population is needed.

show abstract

“…M. abscessus remains a challenge for clinicians due to its large spectrum of virulence and resistance mechanisms [56 ▪ ]. A few case reports described the use of bedaquiline to treat cutaneous NTM disease [57,58]. The use of omadacycline [59], tedizolid [60 ▪ ] and linezolid [61] was also reported in single cases.…”

Section: Mycobacterial Skin Infectionsmentioning

confidence: 99%

Mycobacterial skin infection

Giannotti

Gregori

Matteelli

et al. 2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review The aim of this article is to review the most recent evidences concerning mycobacterial skin infections, limiting the period of literature research to 2020--2021. Recent findings Mycobacterial skin infections include a heterogeneous group of cutaneous diseases. Cutaneous tuberculosis is usually the result of hematogenous dissemination or spread from underlying foci and it must be distinguished from tuberculids, resulting from the immunological reaction to Mycobacterium tuberculosis antigens. Leprosy prevalence was drastically reduced after introduction of multidrug therapy in the 1980 s, but cases are still reported due to underdiagnosis, and animal and environmental reservoirs. Recent advances concentrate in the diagnostic field. Specific guidelines for the treatment of nontuberculous mycobacteria skin infections are missing and surgical procedures may be required. Prognosis is better as compared to nontuberculous mycobacteria lung disease. Rapid laboratory-confirmed diagnosis of Buruli ulcer may be achieved by the IS2404 PCR. Among new drugs, telacebec is promising in terms of potency, shorter duration and tolerability in animal studies. A clinical trial in humans is planned. Summary Mycobacterial cutaneous lesions are nonpathognomonic and clinical suspicion must be confirmed by culture or molecular detection. Long-course multidrug treatment is required based on susceptibility tests. Surgical intervention may also be required. Rehabilitation and psychosocial support reduce long-term physical and mental consequences mostly in Buruli ulcer and leprosy.

show abstract

A disseminated Mycobacterium marinum infection in a renal transplant HIV-infected patient successfully treated with a bedaquiline-containing antimycobacterial treatment: A case report

Cited by 10 publications

References 13 publications

Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis

Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis

Skin and soft tissue infections in solid organ transplants

Mycobacterial skin infection

Contact Info

Product

Resources

About